(NASDAQ: CTMX) Cytomx Therapeutics's forecast annual revenue growth rate of 9.66% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.61%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.12%.
Cytomx Therapeutics's revenue in 2026 is $35,542,000.On average, 11 Wall Street analysts forecast CTMX's revenue for 2026 to be $5,361,369,786, with the lowest CTMX revenue forecast at $853,395,442, and the highest CTMX revenue forecast at $18,287,045,196. On average, 11 Wall Street analysts forecast CTMX's revenue for 2027 to be $5,769,345,056, with the lowest CTMX revenue forecast at $426,697,721, and the highest CTMX revenue forecast at $19,361,409,101.
In 2028, CTMX is forecast to generate $11,310,755,157 in revenue, with the lowest revenue forecast at $4,266,977,212 and the highest revenue forecast at $19,361,409,101.